Combination Vaccines Market Size - By Technology (Conjugate, Live, Inactivated), Age Group (Pediatric, Adult), Application (Diphtheria, Tetanus, & Pertussis (DTP), Polio, Hepatitis B, Influenza), End-use (Hospitals, Clinics) & Forecast, 2023 - 2032

Combination Vaccines Market Size

Combination Vaccines Market size was valued at USD 4.6 billion in 2022 and is anticipated to expand at over 10.9% CAGR from 2023 to 2032 driven by growing emphasis on preventive healthcare globally, with a focus on vaccination as a crucial preventive measure. The global market for vaccines is projected to reach USD 96.3 billion during the forecast period.
 

The combination vaccines offer a comprehensive approach by providing protection against multiple diseases in a single shot. This convenience improves patient compliance and increases vaccination rates, thereby supplementing the industry growth. Additionally, increasing government initiatives such as funding, awareness campaigns, and vaccination mandates will drive the combination vaccines market demand.

COVID-19 Impact

The COVID-19 pandemic had a negative impact on the growth of combination vaccines market. The increased focus on developing and distributing vaccines specifically targeting the coronavirus has led to a diversion of resources, attention, and funding away from other vaccine development projects, including combination vaccines for non-COVID diseases. This shift in priorities have slowed down the progress and research in the field of combination vaccines.
 

Similarly, disruptions in the global supply chain, manufacturing processes, and clinical trials caused by the pandemic have affected the availability and timely introduction of combination vaccines, thereby fostering the business development. Furthermore, the uncertainty and economic challenges posed by the pandemic have also impacted healthcare budgets and investments, potentially affecting the funding and support for the development and distribution of combination vaccines, therefore, hampering the market growth in 2020.
 

Combination Vaccines Industry Trends

The increasing prevalence of infectious diseases, such as influenza, hepatitis, and diphtheria is expected to boost the combination vaccines market expansion. Also, according to the Pan American Health Organization report, approximately 10,000 new hepatitis B infections occur each year, and 23,000 deaths. As infectious diseases continue to pose significant health risks, there is a growing need for effective vaccination strategies, thereby augmenting the market growth. Furthermore, the increasing awareness among population pertaining to the benefits of combination vaccines including hepatitis B vaccine in managing infectious diseases will create a favourable market opportunity for businesses operating in the combination vaccines sector.
 

Combination Vaccines Industry Restraint

Stringent regulatory requirements may hamper the combination vaccines industry progression. The development and approval process for these vaccines involves meeting rigorous regulatory standards, that can be time-consuming, complex, and expensive. Also, the complex nature of combination vaccines, with multiple antigens and potential interactions, requires extensive safety and efficacy evaluations. Such factors will create entry to entry for manufacturers and prolong time to promote the new combination vaccines, thereby hampering the market statistics.
 

Combination Vaccines Market Analysis

The pediatric segment accounted for 56.5% of the combination vaccines market share in 2022 and is set to witness considerable growth over the analysis timeframe. Increasing pediatric population will accelerate the business growth. As the pediatric population expands, there is a growing demand for effective immunization strategies to protect children from various diseases. Such growing immunization demand will foster the sector growth. In addition, the advancements in vaccine technology and manufacturing capabilities have facilitated the development of safer and more effective combination vaccines for children, thus augmenting the industry statistics.
 

The conjugate combination vaccine industry will cross a valuation of USD 5.1 billion by 2032. The use of conjugate technology in combination vaccines offers several advantages, including improved vaccine efficacy, enhanced immune memory, and increased immunogenicity. Such associated advantages will drive the segment growth. Moreover, increasing investments in research and development by both pharmaceutical companies and government organizations is expected to contribute to the industry development in the forthcoming year.
 

The influenza segment is likely to observe 11.9% growth rate during 2023-2032. Influenza, or the flu, is a highly contagious respiratory illness that poses a significant public health concern worldwide. For instance, according to the Centers for Disease Control and Prevention (CDC) report, from 2021-2022 influenza season, influenza was associated with 9 million illnesses, 4 million medical visits, 10,000 hospitalizations, and 5,000 deaths. Therefore, the demand for influenza vaccines is rising, owing to the seasonal nature of the virus and potential complications, particularly among vulnerable populations such as the elderly and those with compromised immune systems. Such aforementioned factor is expected to positively impact the combination vaccines market outlook.
 

The hospitals sector dominated the industry share of 61.9% and is expected to grow at a considerable growth over the analysis timeframe. Hospitals play a crucial role in providing comprehensive healthcare services including vaccination programs, thereby fostering the segmental expansion. However, hospitals often have access to a wide range of patient populations, including those at higher risk of infectious diseases. This will provide an opportunity to increase the uptake of combination vaccines and promote preventive healthcare practices within the hospital community, thereby accelerating the business statistics in the future.
 

North America combination vaccines market captured 40.8% of the global share in 2022 and is said to foresee significant growth till 2032. Favorable regulatory environment coupled with increasing prevalence of infectious diseases is expected to garner the regional growth. Additionally, collaborations between pharmaceutical companies, research institutions, and government organizations in the region will lead to advancements in vaccine research and development. These collaborations will promote innovation, thereby accelerating the development of new combination vaccines, and aiding to the growth of the industry.
 

Combination Vaccines Market Share

Major players operating in the combination vaccines business landscape are

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Merck & Co., Inc.
• Panacea Biotec
• Sinovac Biotech
• Serum Institute of India

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition. Also, kindly note that the company profile section include both companies that have commercial drug available in market as well as those that are into clinical phase development.
 

Combination Vaccines Industry News:

• In June 2021, Merck, and Sanofi’s Vaxelis, a six-in-one pediatric combination vaccine approved in the U.S. VAXELIS is the hexavalent (six-in-one) combination vaccine indicated for active immunization to help prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b. This strategy helped the company to expand its customer base.
   
• In September 2020, Sanofi Pasteur India, the vaccines global business unit of Sanofi launched Tetraxim, a DTaP-IPV booster vaccine in India for preschoolers. This booster vaccine provides protection against four major diseases - Diphtheria, Pertussis, Tetanus, and polio. This strategy helped the company to expand and grow.
   

This combination vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

Market, By Age Group

• Pediatric
• Adult

Market, By Technology

• Conjugate
• Live
• Recombinant
• Inactivated
• Toxoid
• Other Technologies

Market, By Application

• Diphtheria, Tetanus, and Pertussis (DTP)
• Polio
• Hepatitis B
• Influenza
• Hepatitis A
• Varicella (chickenpox)
• Measles, Mumps, and Rubella (MMR)
• Other Applications

Market, By End-use

• Hospitals
  • Public Hospitals
  • Private Hospitals
• Clinics
• Other End-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa